This retrospective cohort study was performed between January 2017 and January 2022 at the Fertility Unit of the Hospital Jiaxing Maternity and Child Health Care Hospital, Zhejiang, China. All the studies were conducted in accordance with the Declaration of Helsinki (1964). Inclusion criteria for eligible patients were as follows: body mass index (BMI ≥ 30 kg/m2); age 18 to 38 years; first IVF/intracytoplasmic sperm injection (ICSI) cycle; short-acting gonadotropin-releasing hormone (GnRH) agonist long protocol; women were excluded from the trial if they had diminished ovarian reserve (defined as an antral follicle count of ≤5 or baseline follicle-stimulating hormone levels ≥ 10 IU/L), irregular uterine bleeding, oocyte donation, pre-implantation genetic diagnosis, and Cushing syndrome.
We advised obese women to participate in a weight management program for 3 to 6 months before undergoing their first IVF/ICSI cycle. Women were divided into 2 groups according to the weight loss goal of 5%: weight reduction group A (≥weight loss goal of 5%) and control group A (
We advised obese women to participate in a weight management program for 3 to 6 months before undergoing their first IVF/ICSI cycle. Women were divided into 2 groups according to the weight loss goal of 5%: weight reduction group A (≥weight loss goal of 5%) and control group A (
